Curioler — home
Behaviour
Tier 1 · Strong research evidence

Why this tier: Systematic review or meta-analysis

Systematic review

Managing hyperactivity in autistic children: medicines, therapies and what the evidence supports

A meta-analysis of 25 randomised trials found methylphenidate and atomoxetine reduce hyperactivity and inattention in autistic children, with small-to-moderate effects. On the therapy side, a meta-analysis of 23 exercise trials found a moderate reduction in behavioural problems, parent training beat parent education for disruptive behaviour at home over 24 weeks, and melatonin reliably improves sleep, which often drives daytime restlessness. Omega-3 and sensory integration have much weaker support, and evidence quality across the board is rated low.

Published 18 September 2026 · 8 min read

What is it?
Hyperactivity in autistic children is usually studied as co-occurring ADHD symptoms, and it has been tested with both medicines and therapies. Pooled randomised trials show that methylphenidate and atomoxetine reduce hyperactivity, that exercise-based programmes improve behavioural problems, and that parent training helps disruptive behaviour at home more than it shifts core hyperactivity.
Why does it matter?
Hyperactivity is one of the most disruptive day-to-day difficulties families report, affecting school, sleep, safety and family life. Seeing which medicines and which therapies actually have trial evidence behind them, and how large or small each effect is, helps caregivers weigh the options and ask better questions of their child's clinician.
When is it relevant?
This is relevant when constant movement, restlessness or impulsivity is getting in the way of learning, safety or family routines, and you are weighing up therapy options, a co-occurring ADHD assessment, or a medication trial.

At a glance

Sample size: Medicines: 25 RCTs pooled (plus a 2025 review of 32 studies). Therapies: 23 exercise RCTs, 11 physical-activity RCTs (346 children), a 24-week parent training RCT, and 6 omega-3 RCTs (194 children)
Demographics: Children and young people with autism spectrum disorder, mostly aged 3-18; medication trials generally ran under 25 years and often excluded children with significant intellectual disability
Key outcome: Methylphenidate reduced hyperactivity by a standardised mean difference of -0.63 (parent-rated) and -0.81 (teacher-rated); atomoxetine -0.49 parent-rated. Exercise interventions reduced behavioural problems by SMD -0.674 across 23 RCTs. Omega-3 produced only a small, borderline effect on hyperactivity (Hedges g = -0.35, confidence interval crossing zero).
Methodology: Several systematic reviews and meta-analyses of randomised controlled trials, pooled with random-effects models. Medication effects come from parent and teacher rating scales; therapy effects come from trials of exercise programmes, behavioural parent training, supplements and sleep treatment, each pooled separately.
Researchers: Rebecca Rodrigues, Meng-Chuan Lai, Stephanie H Ameis, Carmela De Domenico, Francesca Cucinotta, Karen Bearss, Lawrence Scahill, David Daley
Institutes: Western University, Canada, Centre for Addiction and Mental Health, Toronto, The Hospital for Sick Children, Toronto, Autism Research Centre, University of Cambridge, Emory University, IRCCS Centro Neurolesi Bonino-Pulejo, Messina

Limitations:

  • Only a handful of medication trials existed per drug (4 for methylphenidate, 4 for atomoxetine), and most were small and short
  • Overall quality of evidence was rated low to very low, so future trials could change these numbers
  • No trial examined long-term continued use, which is how these medicines are usually taken
  • Most outcomes rest on parent and teacher questionnaires rather than direct observation, and raters are often not blind to treatment
  • Exercise and parent training trials are hard to blind, so their effects are likely flattered by rater expectations; in ADHD research, behavioural intervention effects shrink sharply when blinded measures are used
  • Therapy trials were mostly small, short, and varied widely in what they delivered, so 'exercise' or 'parent training' covers very different programmes
  • Trials rarely included autistic children with significant intellectual disability or minimal speech, so findings may not transfer to every child

What this research found

  • Hyperactivity in autistic children is most often studied as co-occurring ADHD, which is common in autism and adds meaningfully to day-to-day difficulty.
  • Medicines have the strongest direct evidence: methylphenidate (a stimulant) produced moderate to large reductions in hyperactivity on both parent and teacher ratings, and atomoxetine (a non-stimulant) reduced parent-rated hyperactivity and inattention, sometimes also reducing stereotyped behaviour and social withdrawal.
  • Extended-release guanfacine reduced hyperactivity, irritability and repetitive behaviour in a placebo-controlled trial of 62 children and a 2025 multi-centre clinic study of 29 children, and is often used when stimulants are not tolerated.
  • Exercise is the therapy with the most supportive data: a meta-analysis of 23 randomised and quasi-randomised trials found a moderate improvement in behavioural problems (SMD -0.674), with martial arts and ball games standing out, and a separate pooling of 11 trials found gains in inhibitory control, the skill behind 'stop and think'.
  • Behavioural parent training helps, but selectively. A 24-week randomised trial found parent training beat parent education for disruptive behaviour at home, though the authors noted the clinical significance was unclear; in a trial pairing it with atomoxetine, parent training alone did not separate from placebo on core ADHD symptoms over four weeks.
  • Sleep treatment is an indirect but well-evidenced route: melatonin reliably improves how quickly autistic children fall asleep and how long they sleep, with mild side effects, and poor sleep is a common driver of daytime restlessness.
  • Omega-3 supplements showed a small, borderline reduction in hyperactivity across 6 trials, several times weaker than methylphenidate or risperidone in the same rating scale, though with far fewer side effects.
  • Sensory integration therapy and other occupational-therapy approaches are widely used but their reviews report mixed, low-quality evidence for reducing hyperactivity specifically.
  • Side effects across medication trials clustered around sleep difficulties, reduced appetite, irritability and stomach upset, with drowsiness and dizziness more typical of guanfacine.

What this means for caregivers

  • There is a real therapy route worth trying, not only a medication route. Regular, structured physical activity has the best evidence of the non-drug options, is low risk, and fits into ordinary family life.
  • Think about what each approach is actually for. Medicines target hyperactivity most directly; parent training targets difficult behaviour at home and your own toolkit; exercise supports self-control and behaviour broadly; melatonin fixes sleep, which may be feeding the restlessness.
  • Before or alongside anything else, it is worth checking whether sleep problems, anxiety, pain, sensory overload or an unsuitable classroom are driving the hyperactivity, because those have their own fixes.
  • If hyperactivity remains a major difficulty, it is reasonable to ask whether a co-occurring ADHD assessment would be useful, since that is the door most of the medication evidence sits behind.
  • Medication is not a single decision: methylphenidate has the strongest pooled effect, while atomoxetine and guanfacine are alternatives when stimulants are not tolerated. Expect a try-and-review approach rather than a guaranteed result.
  • Ask your clinician what will be monitored and when. Appetite, sleep, irritability, weight, heart rate and blood pressure all appear in these trials as things worth watching.
  • Be cautious with supplements marketed for hyperactivity. Omega-3 has a genuine but small signal; most other products sold for this have no trial evidence in autistic children at all.

Important caveats

  • This is a summary of research, not medical advice. Decisions about medication belong with your child's doctor, who knows their full history.
  • The evidence was graded low to very low quality. That does not mean these treatments do not work, but that studies were few, small and short, and conclusions could shift.
  • Therapy trials are especially vulnerable to expectation effects, because parents and teachers usually know which children received the programme. In broader ADHD research, behavioural intervention effects shrink substantially once blinded raters are used.
  • 'Exercise' and 'parent training' are umbrella terms covering very different programmes, so a specific local service may not match what was tested.
  • Effect sizes come from rating scales that capture impressions rather than objective measurement.
  • Children in these trials were often those without significant intellectual disability, so the findings may not describe every child's likely response.

Sources

Related topics

This summary was prepared by the Curioler research agent. It is not medical advice. Always consult a qualified professional before making decisions about your child's care.

Reviewed by Bhavin Solanki, caregiver parent. This is informational content, not medical advice — see our disclaimer.